{"filing":{"accession_number":"0001171843-26-004977","cik":"0000898437","ticker":"ANIK","company_name":"Anika Therapeutics, Inc.","form":"8-K","filing_date":"2026-07-29","report_date":"2026-07-29","primary_document":"f8k_072926.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/898437/000117184326004977/f8k_072926.htm"},"events":[{"id":21398,"run_id":19299,"accession_number":"0001171843-26-004977","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a standard earnings release disclosing Anika's Q2 2026 financial results, including revenue of $32.6 million (up 16% YoY), net income of $3.3 million, and adjusted EBITDA of $7.1 million. The company also raised full-year 2026 guidance and revised 2027 revenue forecasts. The press release is furnished as Exhibit 99.1 under Item 2.02, which is the standard Item for earnings disclosures.","company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","filing_date":"2026-07-29","form":"8-K","submitted_at":null,"items":[{"id":21031,"accession_number":"0001171843-26-004977","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a standard earnings release disclosing Anika's Q2 2026 financial results, including revenue of $32.6 million (up 16% YoY), net income of $3.3 million, and adjusted EBITDA of $7.1 million. The company also raised full-year 2026 guidance and revised 2027 revenue forecasts. The press release is furnished as Exhibit 99.1 under Item 2.02, which is the standard Item for earnings disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-29T11:21:52.088643+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":21031,"accession_number":"0001171843-26-004977","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a standard earnings release disclosing Anika's Q2 2026 financial results, including revenue of $32.6 million (up 16% YoY), net income of $3.3 million, and adjusted EBITDA of $7.1 million. The company also raised full-year 2026 guidance and revised 2027 revenue forecasts. The press release is furnished as Exhibit 99.1 under Item 2.02, which is the standard Item for earnings disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-29T11:21:52.088643+00:00","company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","filing_date":"2026-07-29"}]}